407 related articles for article (PubMed ID: 31227926)
1. Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies.
Lippner EA; Lewis DB; Robinson WH; Katsumoto TR
Curr Treat Options Oncol; 2019 Jun; 20(7):62. PubMed ID: 31227926
[TBL] [Abstract][Full Text] [Related]
2. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
[TBL] [Abstract][Full Text] [Related]
3. Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors.
Tateo V; Manuzzi L; De Giglio A; Parisi C; Lamberti G; Campana D; Pantaleo MA
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260538
[TBL] [Abstract][Full Text] [Related]
4. Alterations of the immune system in thymic malignancies.
Weksler B; Lu B
J Thorac Oncol; 2014 Sep; 9(9 Suppl 2):S137-42. PubMed ID: 25396311
[TBL] [Abstract][Full Text] [Related]
5. Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs.
Perrino M; Voulaz E; Balin S; Cazzato G; Fontana E; Franzese S; Defendi M; De Vincenzo F; Cordua N; Tamma R; Borea F; Aliprandi M; Airoldi M; Cecchi LG; Fazio R; Alloisio M; Marulli G; Santoro A; Di Tommaso L; Ingravallo G; Russo L; Da Rin G; Villa A; Della Bella S; Zucali PA; Mavilio D
Front Immunol; 2024; 15():1288045. PubMed ID: 38629065
[TBL] [Abstract][Full Text] [Related]
6. Paraneoplastic syndromes in thymoma: an immunological perspective.
Nelson RP; Pascuzzi RM
Curr Treat Options Oncol; 2008 Dec; 9(4-6):269-76. PubMed ID: 19199040
[TBL] [Abstract][Full Text] [Related]
7. Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis.
Okumura M; Fujii Y; Shiono H; Inoue M; Minami M; Utsumi T; Kadota Y; Sawa Y
Gen Thorac Cardiovasc Surg; 2008 Apr; 56(4):143-50. PubMed ID: 18401674
[TBL] [Abstract][Full Text] [Related]
8. Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor.
Jing X; Zhu H; Li Y; Jia W; Zhai X; Li J; Yu J
Immunotherapy; 2022 Oct; 14(14):1097-1107. PubMed ID: 36093721
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
Rajan A; Heery CR; Thomas A; Mammen AL; Perry S; O'Sullivan Coyne G; Guha U; Berman A; Szabo E; Madan RA; Ballester LY; Pittaluga S; Donahue RN; Tsai YT; Lepone LM; Chin K; Ginty F; Sood A; Hewitt SM; Schlom J; Hassan R; Gulley JL
J Immunother Cancer; 2019 Oct; 7(1):269. PubMed ID: 31639039
[TBL] [Abstract][Full Text] [Related]
10. Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database.
Padda SK; Yao X; Antonicelli A; Riess JW; Shang Y; Shrager JB; Korst R; Detterbeck F; Huang J; Burt BM; Wakelee HA; Badve SS
J Thorac Oncol; 2018 Mar; 13(3):436-446. PubMed ID: 29191778
[TBL] [Abstract][Full Text] [Related]
11. Paraneoplastic autoimmunity in thymus tumors.
Marx A; Schultz A; Wilisch A; Helmreich M; Nenninger R; Müller-Hermelink HK
Dev Immunol; 1998; 6(1-2):129-40. PubMed ID: 9716914
[TBL] [Abstract][Full Text] [Related]
12. Thymoma.
Morgenthaler TI; Brown LR; Colby TV; Harper CM; Coles DT
Mayo Clin Proc; 1993 Nov; 68(11):1110-23. PubMed ID: 8231276
[TBL] [Abstract][Full Text] [Related]
13. Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy.
Perrino M; Cordua N; De Vincenzo F; Borea F; Aliprandi M; Cecchi LG; Fazio R; Airoldi M; Santoro A; Zucali PA
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067278
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword.
Ballman M; Zhao C; McAdams MJ; Rajan A
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565190
[TBL] [Abstract][Full Text] [Related]
15. Understanding the landscape of immunotherapy in thymic epithelial tumors.
Maniar R; Loehrer PJ
Cancer; 2023 Apr; 129(8):1162-1172. PubMed ID: 36808725
[TBL] [Abstract][Full Text] [Related]
16. From basic immunobiology to the upcoming WHO-classification of tumors of the thymus. The Second Conference on Biological and Clinical Aspects of Thymic Epithelial Tumors and related recent developments.
Marx A; Müller-Hermelink HK
Pathol Res Pract; 1999; 195(8):515-33. PubMed ID: 10483582
[TBL] [Abstract][Full Text] [Related]
17. Thymic neoplasms.
Debono DJ; Loehrer PJ
Curr Opin Oncol; 1996 Mar; 8(2):112-9. PubMed ID: 8727303
[TBL] [Abstract][Full Text] [Related]
18. [Pathogenesis of autoimmunity in thymoma].
Marx A; Perez J; Greiner A; Schulz A; Kirchner T; Müller-Hermelink HK
Verh Dtsch Ges Pathol; 1993; 77():282-6. PubMed ID: 7511298
[TBL] [Abstract][Full Text] [Related]
19. Pathomechanisms of paraneoplastic myasthenia gravis.
Ströbel P; Preisshofen T; Helmreich M; Müller-Hermelink HK; Marx A
Clin Dev Immunol; 2003 Mar; 10(1):7-12. PubMed ID: 14575152
[TBL] [Abstract][Full Text] [Related]
20. Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review.
Konstantina T; Konstantinos R; Anastasios K; Anastasia M; Eleni L; Ioannis S; Sofia A; Dimitris M
Lung Cancer; 2019 Sep; 135():29-32. PubMed ID: 31446999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
